HCP | Jotup

Optimizing Monoclonal Antibody Production: Temperature and Osmolality's Impact, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Thursday, January 18, 2024

Imperial College London, Protein, Death, Immortalised cell line, CHO, Chinese hamster ovary cell, Metabolism, Temperature, HCP, A-DNA, Vaccine

TORONTO, Jan. 18, 2024 /PRNewswire-PRWeb/ -- Over the past two decades, the biopharmaceutical market has expanded, with monoclonal antibodies exhibiting a 26 percent higher approval rate than other drugs. The market value of monoclonal antibodies alone is expected to reach more than $300 billion USD by 2025. Monoclonal antibodies are recombinant proteins that are extracellularly secreted by mammalian cells, such as Chinese hamster ovary (CHO) cells. Advances in monoclonal antibody production technology and manufacturing strategies have led to increased yield, which is, however, accompanied by increased levels of impurities, such as host cell proteins (HCPs).

Key Points:

In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies.
Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant.
The featured speaker will discuss how temperature and osmolality in the cell culture can be optimized, seeking improved monoclonal antibody production efficiency.
Join this webinar to investigate the effects of simultaneously adjusting temperature and osmolality on the generation of HCPs, antibody yield and cell growth.

Everest Group Recognizes ODAIA for Market Impact, Vision, and Capability

Retrieved on:

Wednesday, January 17, 2024

Acadia Pharmaceuticals, Patient, Health, PEAK, Prescription, Blog, HCP, CEP, Therapy, Organization, Marketing, Vaccine, Data science, Pharmaceutical industry

TORONTO, Jan. 17, 2024 /PRNewswire/ -- Cutting-edge AI company, ODAIA, today announced it was named a Major Contender in the Life Sciences Next-generation Customer Engagement Platforms (CEP) PEAK Matrix® Assessment 2023 from Everest Group. As the life sciences industry continues its rapid shift to digital and delivering personalized healthcare professional (HCP) experiences, innovative biopharma companies, including 2 of the top 15 pharma companies, are using ODAIA to give their commercial teams near real-time, predictive data insights to target and engage HCPs and get life-changing therapies to patients faster.

Key Points:

TORONTO, Jan. 17, 2024 /PRNewswire/ -- Cutting-edge AI company, ODAIA , today announced it was named a Major Contender in the Life Sciences Next-generation Customer Engagement Platforms (CEP) PEAK Matrix® Assessment 2023 from Everest Group.
We're excited about the potential of ODAIA helping us get breakthrough neuroscience solutions to patients faster and more effectively."
The process of getting treatments to market remains manual and time-consuming for many sales and marketing organizations.
With ODAIA, commercial organizations can uncover new market dynamics and deliver near-real-time and predictive insights across their commercial teams, while ensuring consistency in their data and analytics.

Alucio™ Makes Major Strides, Finishing Record Year in 2023

Retrieved on:

Tuesday, January 16, 2024

Artificial intelligence, Research, SAN, ARR, HCP, CLM, Market access, KOL, Machine learning, Medical science liaison

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Alucio ™, a fast-growing provider of cloud-based software for the life sciences industry, delivered noteworthy results in 2023, and continued to deepen and extend Beacon's scientific exchange capabilities for users. Beacon, the company's flagship product, is a modern content activation and HCP engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points:

"We are very proud of what we were able to achieve as an organization in 2023.
In fact, Alucio achieved 100% customer retention in 2023 with all clients remaining active and referenceable.
"We are very proud of what we were able to achieve as an organization in 2023.
"We'll continue to innovate and work to delight our customers in 2024 to further sustain our success."

Doceree expands Leadership Team in North America with Top Talents from AdTech and Ad agencies

Retrieved on:

Tuesday, January 16, 2024

Kamya Elawadhi, formerly the Senior Vice President (North America & EU) and Corporate Strategy - Customer Success at Doceree, has been elevated to the role of Chief Client Officer.

Key Points:

Kamya Elawadhi, formerly the Senior Vice President (North America & EU) and Corporate Strategy - Customer Success at Doceree, has been elevated to the role of Chief Client Officer.
Known for her substantial contributions in scaling Doceree's global operations being a founding team member, Elawadhi in her new capacity, will lead the charge in elevating and differentiating the way Doceree partners with clients.
Her appointment underscores her instrumental role in fortifying Doceree's market position, marking a strategic move for sustained growth and enhanced client engagement.
In her role at Doceree, Sciorra will build and scale global marketing operations to fuel the company's fast growth.

Pulse Health Unveils Request a Rep, a Seamless Connection Between Engaged HCPs and Relevant Field Force Reps

Retrieved on:

Tuesday, January 16, 2024

Cloud, Software as a service, HCP, Communication, Software, Marketing, Pulse, Automation, Hospira, Sales

NEW YORK, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Today, Pulse Health announced the launch of Request a Rep, providing pharma with cutting-edge technology to seamlessly capture, analyze and connect HCPs that visit a brands website with the most relevant field force reps.

Key Points:

Delivering significant innovation to the life science industry, Request a Rep can be leveraged within the Pulse Engagement Cloud or as a standalone product.
Historically, when a healthcare provider visited a brand's website and requested information, they entered a general database.
With Request a Rep enabled, Pulse leverages its proprietary technology to analyze the captured data and direct it to the most relevant field force representative.
This all-in-one Software as a Service (SaaS) solution effortlessly integrates marketing automation, advanced segmentation, centralized databases, omni-channel marketing, and brand-specific analytics and insights.

Komodo Health Unveils New Annual Report Illuminating the State of Data Mining in Life Sciences

Retrieved on:

Tuesday, January 9, 2024

Komodo Health today unveiled findings from a new, first-of-its kind survey detailing the challenges to obtaining data-driven insights that continue to impede progress across the U.S. Life Sciences organizations.

Key Points:

Komodo Health today unveiled findings from a new, first-of-its kind survey detailing the challenges to obtaining data-driven insights that continue to impede progress across the U.S. Life Sciences organizations.
Conducted independently by Frost & Sullivan, the new blinded survey benchmarks the current state of real-world data (RWD) and analytics, exposing the complexities that teams face in generating meaningful insights — as reported by Life Sciences leaders, middle managers, and data scientists/analysts.
For the largest U.S. Life Sciences enterprises, these numbers are even higher as organizations wrestle with uneven access to disparate data types, low confidence in data accuracy, and time-consuming data integration.
Time investment: Approximately 70% of teams spend six or more months transforming data into a usable state to extract insights, delaying drug research, development, and delivery.

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Retrieved on:

Tuesday, January 9, 2024

“In 2023, VOWST received FDA approval with a broad indication, which includes use in first recurrence patients.

Key Points:

“In 2023, VOWST received FDA approval with a broad indication, which includes use in first recurrence patients.
The SER-155 Cohort-2 readout is expected in the third quarter, and we are excited to announce receipt of Fast Track Designation for SER-155 to reduce the risk of infection and GvHD in allo-HSCT patients.
Production of VOWST commercial supply enabled a strong commercial launch within weeks of approval; progress in expansion of VOWST manufacturing capacity.
To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch .

Doceree concludes Season 1 of 'The Next Marketing With HJ' with a stellar finale featuring WPP's Chief Creative Officer, Rob Reilly

Retrieved on:

Tuesday, January 9, 2024

Senior, Avalere Health, Digital health, Season 2, Harshit, HJ, Knowledge, Season, Stand Up and Scream, WPP, HCP, Anecdote, Series finale, Marketing, Season One, Tourism

PARSIPPANY, N.J. , Jan. 9, 2024 /PRNewswire/ -- Doceree, the leading global platform for HCP programmatic marketing, concluded 2023 on a new high as Harshit Jain MD, Founder & Global CEO, Doceree, exchanged revolutionary insights with Rob Reilly, Global Chief Creative Officer, WPP, about the paramount value of culturally inclusive marketing in today's digital age, in the final episode of the refreshing knowledge-first series, 'The Next Marketing with HJ'.

Key Points:

Launched on Doceree's YouTube channel on 1st August 2023, Season 1 of the first-of-its-kind talk show hosted by Harshit Jain MD encourages dynamic knowledge-sharing with global marketing/advertising experts through eight enriching and entertaining episodes.
As the new-age marketers strive to build authentic relationships and connections, the entertaining series serves as a guide through the ever-changing landscape of healthcare marketing.
I am immensely grateful to all the experts who supported me in this endeavour and am all set to launch Season 2 soon."
Reflecting on his participation in the show, Rob Reilly, Chief Creative Officer at WPP, says, "As creatives, it's essential to be curious and to look for inspiration and knowledge in unexpected places.

HashiCorp appoints Michael Weingartner as Chief Product Officer, promotes Talha Tariq to Chief Information Officer and Chief Security Officer

Retrieved on:

Monday, January 8, 2024

Cloud, HashiCorp, SAP, Google Cloud, Microsoft, Anki, Research, HCP, SAN, PwC, CIO, FinancialForce.com, Knowledge, Weingartner, CPO, CSO, Organization, Automation, Management

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leader in multi-cloud infrastructure automation software, today announced that Michael Weingartner has joined HashiCorp as its first Chief Product Officer (CPO), and that Talha Tariq has been promoted to Chief Information Officer (CIO) and Chief Security Officer (CSO).

Key Points:

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leader in multi-cloud infrastructure automation software, today announced that Michael Weingartner has joined HashiCorp as its first Chief Product Officer (CPO), and that Talha Tariq has been promoted to Chief Information Officer (CIO) and Chief Security Officer (CSO).
His experience will be invaluable as we continue to scale HashiCorp,” said Dave McJannet, CEO, HashiCorp.
Armon Dadgar will continue in his role as Chief Technology Officer, where he interacts daily with HashiCorp customers and partners.
Prior to HashiCorp, Tariq served as Chief Information Security Officer at Anki and FinancialForce and held various security leadership positions at PwC and Microsoft.

Evoke unveils simplified brand and structure: Inizio Evoke

Retrieved on:

Monday, January 8, 2024

Professional corporation, HCP, International, Transformation, Access, Data communication, Health, Evoke, Patient, Thought, DTC, Advertising, Growth, Creativity, Automation, CX, Kyne, Online shopping

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Evoke, an Inizio company, today announces it has simplified its brand and enhanced its offerings to ensure clients receive the most effective solutions tailored to the dynamic healthcare landscape. With this simplified brand ecosystem, the platform unites its specialty agencies and capabilities under a singular Inizio Evoke brand and core service areas in Marketing, Comms, Transformation, Media, and Access. As one integrated platform, Inizio Evoke now delivers a more advanced offering and more intuitive experience for its clients and people. It further connects global capabilities to deliver the best thinking and provide clients with best-in-industry work, creative, and innovative solutions.

Key Points:

With this simplified brand ecosystem, the platform unites its specialty agencies and capabilities under a singular Inizio Evoke brand and core service areas in Marketing, Comms, Transformation, Media, and Access.
"Building on our decades-long legacy of innovation, creativity, and impact in healthcare, our new unified brand reflects our commitment to our clients," said Reid Connolly, CEO of Inizio Evoke.
Evoke specialty agencies are now operating under the new Inizio Evoke brand as follows:
Inizio Evoke: Combines the global marketing expertise of Evoke North America, Evoke Europe, and Evoke Mind+Matter UK to deliver full-service brand marketing, advertising, and creative capabilities that harness data-driven insights to deliver transformative impact across DTC, Patient, and HCP audiences.
Inizio Evoke Comms: Integrates the specialized experience from Evoke Canale, Evoke Galliard, and Evoke Kyne to deliver award-winning global health communications for clients across pharma, biopharma, biotech, and non-profit.